Resultat 1 - 8 av 8
Desert Control Releases Q3 2024 Report and Year-to-Date Company Update
Sandnes, Norway, 15 November 2024 — Desert Control AS (DSRT) announces its third-quarter report and interim financial results for the fiscal period ending 30 September 2024. Desert Control continued its positive momentum in the third quarter of 2024, achievingSammanhang: ...Desert Control continued its positive momentum in the third quarter of 2024, achieving milestones in market expansion, pilot progress, and initiation of licensing revenues in the Middle East. The quarter saw strong results from pilots in agriculture and landscaping, supporting negotiations for larger commercial projects in the United States. ...
Omnämnda platser: Norway. Omnämnda personer: Desert Control AS, Desert Control Releases, Company Update Sandnes.
MARSHALL GROUP REPORTS STRONG PROFITABLE GROWTH IN THE THIRD QUARTER
In the third quarter of 2024, Marshall Group continued to build on its strong and profitable growth trajectory with net sales increasing 15 percent to SEK 1,118.4 million (974.4). Adjusted operating profit increased to SEK 304.0 million (236.6) amountingtoSammanhang: ...In the third quarter of 2024, Marshall Group continued to build on its strong and profitable growth trajectory with net sales increasing 15 percent to SEK 1,118.4 million (974.4). ...
Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website
Hamlet BioPharma, ticker HAMLET B, the innovative pharmaceutical company, which develops new therapies against cancer and infections, is pleased to inform that the CEO World Magazine, renowned for its focus on high-level executives and influential businessSammanhang: ...They highlight Hamlet’s recent clinical trials and innovative approach merging groundbreaking research with a strong business vision....
Omnämnda personer: Hamlet BioPharma, clinical trials, Company Spotlight.
Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business
Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 123.1 million compared to 141.0 in the correspondingSammanhang: ...Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business...
Omnämnda platser: Oslo.
Marshall Group reports another strong quarter of growth
Marshall Group continued to build on its momentum into the second quarter of 2024 with net sales increasing 15 percent to SEK 1,097.5 million (956.8). Adjusted operating profit increased to SEK 242.1 million (134.5) amounting to an adjusted operating marginSammanhang: ...Marshall Group reports another strong quarter of growth...
White & Case advises Nobia on multiple strategic transactions
Global law firm White & Case LLP has advised Nobia (the “Company”), a long-term client with whom the firm have shared a strong corporate memory together, on a list of significant strategic transactions.Sammanhang: ...Global law firm White & Case LLP has advised Nobia (the “Company”), a long-term client with whom the firm have shared a strong corporate memory together, on a list of significant strategic transactions....
New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects
Sammanhang: ...New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects...
Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast TrackSammanhang: ...Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug candidate Alpha1H for the treatment of non-muscle invasive bladder cancer. ...
Omnämnda platser: Lund, Sweden. Omnämnda personer: Hamlet BioPharma, Hamlet BioPharma AB.